Spinal cord injury (WP2432)

Mus musculus

This pathway provides an overview of cell types, therapeutic targets, drugs, new proposed targets and pathways implicated in spinal cord injury. Spinal cord injury is a complex multi-step process that involves the regulation of gene expression and signaling in motor neurons, oligodentrocytes, microglia, and astrocytes that trigger immediate immune responses lasting several weeks. Within 24 hours, chemoattractants and cytokines released from the site of injury activate neutrophils which further recruit B and T cells or recruit monocytes that ultimately result in infiltration and activation by microglia and macrophages. These immune responses result in inflammation, excitotoxicity, cell death, formation of glial scar, and suppression of axonal regeneration. An increase in the expression of cell cycle genes further results in proliferation of astrocytes and microglia that leads to apoptosis and necrosis of oligodentrocytes and neurons.

Authors

Nathan Salomonis , Egon Willighagen , Deborah Micael , Chris Evelo , Linda Rieswijk , and Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Mus musculus

Communities

Annotations

Disease Ontology

spinal cord disease post-traumatic stress disorder

Pathway Ontology

disease pathway

Cell Type Ontology

astrocyte of the spinal cord

Participants

Label Type Compact URI Comment
LTB4 Metabolite pubchem.compound:169
NO Metabolite pubchem.compound:145068
melittin Metabolite pubchem.compound:16133648
FK506 Metabolite cas:104987-11-3
Arachidonic acid Metabolite hmdb:HMDB0001043
PGH2 Metabolite hmdb:HMDB0001381
Olomoucine Metabolite hmdb:HMDB0035233
Ngfr GeneProduct ensembl:ENSMUSG00000000120
Tnfsf13 GeneProduct ensembl:ENSMUSG00000089669
Ltb4r1 GeneProduct ensembl:ENSMUSG00000046908
Tnfsf13b GeneProduct ensembl:ENSMUSG00000031497
Ptprz1 GeneProduct ensembl:ENSMUSG00000068748
Pdyn GeneProduct ensembl:ENSMUSG00000027400
Ltb GeneProduct ensembl:ENSMUSG00000024399
Plxna2 GeneProduct ensembl:ENSMUSG00000026640
Cspg4 GeneProduct ensembl:ENSMUSG00000032911
Cd47 GeneProduct ensembl:ENSMUSG00000055447
Zfp36 GeneProduct ensembl:ENSMUSG00000044786
Fcgr2b GeneProduct ensembl:ENSMUSG00000026656
Prb1 GeneProduct ensembl:ENSMUSG00000067543
Ptpra GeneProduct ensembl:ENSMUSG00000027303
Il1b GeneProduct ensembl:ENSMUSG00000027398
Nos2 GeneProduct ensembl:ENSMUSG00000020826
Tnf GeneProduct ensembl:ENSMUSG00000024401
Nr4a1 GeneProduct ensembl:ENSMUSG00000023034
Il4 GeneProduct ensembl:ENSMUSG00000000869
Btg2 GeneProduct ensembl:ENSMUSG00000020423
Cdk2 GeneProduct ensembl:ENSMUSG00000025358
Nos1 GeneProduct ensembl:ENSMUSG00000029361
Il2 GeneProduct ensembl:ENSMUSG00000027720
Il6 GeneProduct ensembl:ENSMUSG00000025746
Tlr4 GeneProduct ensembl:ENSMUSG00000039005
Fos GeneProduct ensembl:ENSMUSG00000021250
Tgfb1 GeneProduct ensembl:ENSMUSG00000002603
Egr1 GeneProduct ensembl:ENSMUSG00000038418
Mmp12 GeneProduct ensembl:ENSMUSG00000049723
Ifng GeneProduct ensembl:ENSMUSG00000055170
Mbp GeneProduct ensembl:ENSMUSG00000041607
Rtn4 GeneProduct ensembl:ENSMUSG00000020458
Hc GeneProduct ensembl:ENSMUSG00000026874
Cxcl1 GeneProduct ensembl:ENSMUSG00000029380
Aqp4 GeneProduct ensembl:ENSMUSG00000024411
Arg1 GeneProduct ensembl:ENSMUSG00000019987
Epha4 GeneProduct ensembl:ENSMUSG00000026235
Efnb2 GeneProduct ensembl:ENSMUSG00000001300
Cxcl10 GeneProduct ensembl:ENSMUSG00000034855
Ccng1 GeneProduct ensembl:ENSMUSG00000020326
Mmp9 GeneProduct ensembl:ENSMUSG00000017737
Ncan GeneProduct ensembl:ENSMUSG00000002341
Slit1 GeneProduct ensembl:ENSMUSG00000025020
Slit2 GeneProduct ensembl:ENSMUSG00000031558
Slit3 GeneProduct ensembl:ENSMUSG00000056427
Ntn1 GeneProduct ensembl:ENSMUSG00000020902
Rgma GeneProduct ensembl:ENSMUSG00000070509
Ccr2 GeneProduct ensembl:ENSMUSG00000049103
Il1r1 GeneProduct ensembl:ENSMUSG00000026072
Il1a GeneProduct ensembl:ENSMUSG00000027399
Cxcl2 GeneProduct ensembl:ENSMUSG00000058427
Ccl2 GeneProduct ensembl:ENSMUSG00000035385
Pla2g6 GeneProduct ensembl:ENSMUSG00000042632
Pla2g5 GeneProduct ensembl:ENSMUSG00000041193
Pla2g2a GeneProduct ensembl:ENSMUSG00000058908
Anxa1 GeneProduct ensembl:ENSMUSG00000024659
Icam1 GeneProduct ensembl:ENSMUSG00000037405
Selp GeneProduct ensembl:ENSMUSG00000026580
Klk8 GeneProduct ensembl:ENSMUSG00000064023
Gfap GeneProduct ensembl:ENSMUSG00000020932
Cdk4 GeneProduct ensembl:ENSMUSG00000006728
Tacr1 GeneProduct ensembl:ENSMUSG00000030043
E2f5 GeneProduct ensembl:ENSMUSG00000027552
Rb1 GeneProduct ensembl:ENSMUSG00000022105
Prkca GeneProduct ensembl:ENSMUSG00000050965
E2f1 GeneProduct ensembl:ENSMUSG00000027490
Mapk1 GeneProduct ensembl:ENSMUSG00000063358
Ccnd1 GeneProduct ensembl:ENSMUSG00000070348
Myc GeneProduct ensembl:ENSMUSG00000022346
Gadd45a GeneProduct ensembl:ENSMUSG00000036390
Mapk3 GeneProduct ensembl:ENSMUSG00000063065
Casp3 GeneProduct ensembl:ENSMUSG00000031628
Trp53 GeneProduct ensembl:ENSMUSG00000059552
Chst11 GeneProduct ensembl:ENSMUSG00000034612
Vcan GeneProduct ensembl:ENSMUSG00000021614
Col4a1 GeneProduct ensembl:ENSMUSG00000031502
Xylt1 GeneProduct ensembl:ENSMUSG00000030657
Col2a1 GeneProduct ensembl:ENSMUSG00000022483
Acan GeneProduct ensembl:ENSMUSG00000030607
Bcan GeneProduct ensembl:ENSMUSG00000004892
Sox9 GeneProduct ensembl:ENSMUSG00000000567
Grin1 GeneProduct ensembl:ENSMUSG00000026959
Vim GeneProduct ensembl:ENSMUSG00000026728
Ppp3ca GeneProduct ensembl:ENSMUSG00000028161
Gap43 GeneProduct ensembl:ENSMUSG00000047261
Fkbp1a GeneProduct ensembl:ENSMUSG00000032966
Mag GeneProduct ensembl:ENSMUSG00000036634
Rhoa GeneProduct ensembl:ENSMUSG00000007815
Rhoc GeneProduct ensembl:ENSMUSG00000002233
Rhob GeneProduct ensembl:ENSMUSG00000054364
Rock2 GeneProduct ensembl:ENSMUSG00000020580
Omg GeneProduct ensembl:ENSMUSG00000049612
Rtn4r GeneProduct ensembl:ENSMUSG00000043811
Lilrb3 GeneProduct ensembl:ENSMUSG00000058818
PTGS2 GeneProduct ncbigene:469616
Nox4 GeneProduct ensembl:ENSMUSG00000030562
Mir23b GeneProduct ensembl:ENSMUSG00000065599
Cdk1 GeneProduct ensembl:ENSMUSG00000019942
Gdnf GeneProduct ensembl:ENSMUSG00000022144
Sema6a GeneProduct ensembl:ENSMUSG00000019647
Gja1 GeneProduct ensembl:ENSMUSG00000050953
Bdnf GeneProduct ensembl:ENSMUSG00000048482

References

  1. Role of cyclooxygenase 2 in acute spinal cord injury. Resnick DK, Graham SH, Dixon CE, Marion DW. J Neurotrauma. 1998 Dec;15(12):1005–13. PubMed Europe PMC Scholia
  2. Improved recovery after spinal cord trauma in ICAM-1 and P-selectin knockout mice. Farooque M, Isaksson J, Olsson Y. Neuroreport. 1999 Jan 18;10(1):131–4. PubMed Europe PMC Scholia
  3. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Eng LF, Ghirnikar RS, Lee YL. Neurochem Res. 2000 Oct;25(9–10):1439–51. PubMed Europe PMC Scholia
  4. A neutrophil elastase inhibitor (ONO-5046) reduces neurologic damage after spinal cord injury in rats. Tonai T, Shiba K, Taketani Y, Ohmoto Y, Murata K, Muraguchi M, et al. J Neurochem. 2001 Sep;78(5):1064–72. PubMed Europe PMC Scholia
  5. Gene profiling in spinal cord injury shows role of cell cycle in neuronal death. Di Giovanni S, Knoblach SM, Brandoli C, Aden SA, Hoffman EP, Faden AI. Ann Neurol. 2003 Apr;53(4):454–68. PubMed Europe PMC Scholia
  6. Axonal plasticity and functional recovery after spinal cord injury in mice deficient in both glial fibrillary acidic protein and vimentin genes. Menet V, Prieto M, Privat A, Giménez y Ribotta M. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8999–9004. PubMed Europe PMC Scholia
  7. Stimulation of production of glial cell line-derived neurotrophic factor and nitric oxide by lipopolysaccharide with different dose-responsiveness in cultured rat macrophages. Hashimoto M, Ito T, Fukumitsu H, Nomoto H, Furukawa Y, Furukawa S. Biomed Res. 2005 Oct;26(5):223–9. PubMed Europe PMC Scholia
  8. Decoy peptides that bind dynorphin noncovalently prevent NMDA receptor-mediated neurotoxicity. Woods AS, Kaminski R, Oz M, Wang Y, Hauser K, Goody R, et al. J Proteome Res. 2006 Apr;5(4):1017–23. PubMed Europe PMC Scholia
  9. Accumulation of the inhibitory receptor EphA4 may prevent regeneration of corticospinal tract axons following lesion. Fabes J, Anderson P, Yáñez-Muñoz RJ, Thrasher A, Brennan C, Bolsover S. Eur J Neurosci. 2006 Apr;23(7):1721–30. PubMed Europe PMC Scholia
  10. Attenuation of astrogliosis by suppressing of microglial proliferation with the cell cycle inhibitor olomoucine in rat spinal cord injury model. Tian D shi, Dong Q, Pan D ji, He Y, Yu Z yuan, Xie M jie, et al. Brain Res. 2007 Jun 18;1154:206–14. PubMed Europe PMC Scholia
  11. Neuropsin promotes oligodendrocyte death, demyelination and axonal degeneration after spinal cord injury. Terayama R, Bando Y, Murakami K, Kato K, Kishibe M, Yoshida S. Neuroscience. 2007 Aug 10;148(1):175–87. PubMed Europe PMC Scholia
  12. Caspase-3 activity is reduced after spinal cord injury in mice lacking dynorphin: differential effects on glia and neurons. Adjan VV, Hauser KF, Bakalkin G, Yakovleva T, Gharibyan A, Scheff SW, et al. Neuroscience. 2007 Sep 7;148(3):724–36. PubMed Europe PMC Scholia
  13. The p75 neurotrophin receptor is essential for neuronal cell survival and improvement of functional recovery after spinal cord injury. Chu GKT, Yu W, Fehlings MG. Neuroscience. 2007 Sep 7;148(3):668–82. PubMed Europe PMC Scholia
  14. Annexin A1 reduces inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in adult rats following spinal cord injury. Liu NK, Zhang YP, Han S, Pei J, Xu LY, Lu PH, et al. J Neuropathol Exp Neurol. 2007 Oct;66(10):932–43. PubMed Europe PMC Scholia
  15. Greatly improved neurological outcome after spinal cord compression injury in AQP4-deficient mice. Saadoun S, Bell BA, Verkman AS, Papadopoulos MC. Brain. 2008 Apr;131(Pt 4):1087–98. PubMed Europe PMC Scholia
  16. Effects of long-term FK506 administration on functional and histopathological outcome after spinal cord injury in adult rat. Saganová K, Orendácová J, Sulla I Jr, Filipcík P, Cízková D, Vanický I. Cell Mol Neurobiol. 2009 Sep;29(6–7):1045–51. PubMed Europe PMC Scholia
  17. Pathogenic antibodies are active participants in spinal cord injury. Dekaban GA, Thawer S. J Clin Invest. 2009 Oct;119(10):2881–4. PubMed Europe PMC Scholia
  18. Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion. Pineau I, Sun L, Bastien D, Lacroix S. Brain Behav Immun. 2010 May;24(4):540–53. PubMed Europe PMC Scholia
  19. Eph receptor tyrosine kinases regulate astrocyte cytoskeletal rearrangement and focal adhesion formation. Puschmann TB, Turnley AM. J Neurochem. 2010 May;113(4):881–94. PubMed Europe PMC Scholia
  20. The LTB4-BLT1 axis mediates neutrophil infiltration and secondary injury in experimental spinal cord injury. Saiwai H, Ohkawa Y, Yamada H, Kumamaru H, Harada A, Okano H, et al. Am J Pathol. 2010 May;176(5):2352–66. PubMed Europe PMC Scholia
  21. CD47 knockout mice exhibit improved recovery from spinal cord injury. Myers SA, DeVries WH, Andres KR, Gruenthal MJ, Benton RL, Hoying JB, et al. Neurobiol Dis. 2011 Apr;42(1):21–34. PubMed Europe PMC Scholia
  22. Current and future therapeutic strategies for functional repair of spinal cord injury. Tohda C, Kuboyama T. Pharmacol Ther. 2011 Oct;132(1):57–71. PubMed Europe PMC Scholia
  23. Prevention of both neutrophil and monocyte recruitment promotes recovery after spinal cord injury. Lee SM, Rosen S, Weinstein P, van Rooijen N, Noble-Haeusslein LJ. J Neurotrauma. 2011 Sep;28(9):1893–907. PubMed Europe PMC Scholia
  24. Repertoire of microglial and macrophage responses after spinal cord injury. David S, Kroner A. Nat Rev Neurosci. 2011 Jun 15;12(7):388–99. PubMed Europe PMC Scholia
  25. Phospholipase A2 superfamily members play divergent roles after spinal cord injury. López-Vales R, Ghasemlou N, Redensek A, Kerr BJ, Barbayianni E, Antonopoulou G, et al. FASEB J. 2011 Dec;25(12):4240–52. PubMed Europe PMC Scholia
  26. Activated microglia inhibit axonal growth through RGMa. Kitayama M, Ueno M, Itakura T, Yamashita T. PLoS One. 2011;6(9):e25234. PubMed Europe PMC Scholia
  27. Critical role of connexin 43 in secondary expansion of traumatic spinal cord injury. Huang C, Han X, Li X, Lam E, Peng W, Lou N, et al. J Neurosci. 2012 Mar 7;32(10):3333–8. PubMed Europe PMC Scholia
  28. PlexinA2 limits recovery from corticospinal axotomy by mediating oligodendrocyte-derived Sema6A growth inhibition. Shim SO, Cafferty WBJ, Schmidt EC, Kim BG, Fujisawa H, Strittmatter SM. Mol Cell Neurosci. 2012 Jun;50(2):193–200. PubMed Europe PMC Scholia
  29. Immunosuppressant FK506: focusing on neuroprotective effects following brain and spinal cord injury. Saganová K, Gálik J, Blaško J, Korimová A, Račeková E, Vanický I. Life Sci. 2012 Aug 21;91(3–4):77–82. PubMed Europe PMC Scholia
  30. p53 Regulates the neuronal intrinsic and extrinsic responses affecting the recovery of motor function following spinal cord injury. Floriddia EM, Rathore KI, Tedeschi A, Quadrato G, Wuttke A, Lueckmann JM, et al. J Neurosci. 2012 Oct 3;32(40):13956–70. PubMed Europe PMC Scholia
  31. Molecular targeting of NOX4 for neuropathic pain after traumatic injury of the spinal cord. Im YB, Jee MK, Choi JI, Cho HT, Kwon OH, Kang SK. Cell Death Dis. 2012 Nov 15;3(11):e426. PubMed Europe PMC Scholia